News
In recognition of World Cloud Security Day on April 3rd, Genetec Inc. ("Genetec"), the global leader in enterprise physical security software, shares key insights and best practices to help ...
This article was medically reviewed by Karie Johnson, DVM, a veterinarian in the south suburbs of Chicago whose focus is on nutrition, osteoarthritis, behavior, and end-of-life care. She is ...
Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these ...
Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...
Pharmacovigilance evolves with technology, employing active surveillance to detect drug-related issues and ensure safety in ...
1d
News-Medical.Net on MSNAdvancing Adherent Cell Assays with SemaCyte® TechnologySemarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...
Accomplished biotech investor with a track record of successful company-building and exits to lead Angelini Ventures’ international BioTech ...
Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...
US pharmaceutical firm Merck & Co plans to build a £1 billion ... at the heart of the city’s life sciences “cluster”. The Financial Times reported that the company expects to employ ...
Merck is also developing a subcutaneous formulation of Keytruda that can extend its patent life. MRK’s Pipeline Progress & Strategic M&A Deals Merck made meaningful regulatory and clinical ...
AskBio Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that its Board of Directors has elected Independent Director Laura Sepp-Lorenzino, PhD, to the ...
With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug. The German pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results